Novocure Enrolls Last Patient in HEPANOVA Trial Testing Tumor Treating Fields in Combination with Sorafenib in Advanced Liver Cancer

Final data collection will occur in six months ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced that the last patient has been enrolled in the HEPANOVA trial, a phase 2 pilot trial testing Tumor Treating Fields in combination with sorafenib in patients with advanced liver cancer. The final data collection date is six months after …

Novocure to Report Second Quarter 2020 Financial Results

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2020 on Thursday, July 30, 2020, before the U.S. financial markets open. Novocure’s management will host a conference call and webcast to discuss its financial results for the three and six months ended June 30, 2020, at …

China NMPA Approves Optune® for the Treatment of Newly Diagnosed and Recurrent Glioblastoma

Optune is the first innovative treatment for glioblastoma approved in China in over 15 years A large, global phase 3 pivotal clinical study in newly diagnosed glioblastoma showed adding Optune to chemotherapy more than doubled the five-year overall survival rate1 ST. HELIER, Jersey & SHANGHAI–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR), a global oncology company with a proprietary …

Novocure Reports First Quarter 2020 Financial Results and Provides Company Update

Quarterly net revenues of $101.8 million, representing 39 percent growth versus the first quarter 2019 and 3 percent growth versus the fourth quarter 2019 Balance sheet strength allows continued investments in innovation and the advancement of commercial and development priorities ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended March …

Novocure Announces Presentation of EF-19 Post-approval Registry Trial Data Studying Optune as a Monotherapy for the Treatment of Recurrent GBM at the American Association for Cancer Research 2020 Virtual Annual Meeting I

EF-19 data confirm the effectiveness and safety of Optune as monotherapy and further strengthen Optune’s clinical profile in recurrent GBM ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced that an abstract highlighting results from the EF-19 post-approval registry trial studying Optune for the treatment of recurrent GBM will be presented as a virtual poster at …

Novocure Provides Business Update Related to COVID-19

Novocure to report first quarter financial results on Thursday, April 30, 2020 ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today provided an update on its response to the global COVID-19 pandemic and an initial evaluation of the impact the pandemic may have on Novocure’s general business operations and clinical trials. The company is taking actions to …

Novocure’s response to COVID-19

Important information for our patients, caregivers and providers As the global impacts of COVID-19 continue to evolve, Novocure is committed to our mission and to transparent communication of our response to our patients, caregivers and providers. Aggressive cancers do not slow because of this global pandemic, and we remain as focused as ever on delivering …

German Federal Joint Committee Updates Medical Care Directive to include Tumor Treating Fields, establishing National Reimbursement for Optune in Germany

Directive mandates reimbursement coverage of Tumor Treating Fields for patients with newly diagnosed glioblastoma by the compulsory health insurance system ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced that the German Federal Joint Committee, or G-BA, has updated its directive for Contracted Medical Care to include Tumor Treating Fields, establishing national reimbursement for Optune in …